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Germany 
Objective: To determine tumor necrosis factor-a (TNF-a) levels in a prospective study in 58 hospitalized patients in a 
department of internal medicine (63 episodes, 29 in immunocompromised patients) during a 7-month period. 
Methods: Patients fulfilling the following criteria were included: clinical evidence of acute infection, temperature 
>38.2"C, tachycardia >90 beatdrnin, tachypnea s20 breathshnin. Samples were taken from day 1 up to day 13 after an 
infection was diagnosed, and TNF-a was determined by enzyme immunoassay. 
Results: In 29 episodes (46.0%) the infection was microbiologically documented. The median of the TNF-a levels in the 
Gram-negative episodes was significantly higher than that in the Gram-positive episodes (p=0.002). Thirteen of 63 
episodes (20.6%) had a fatal outcome. With respect to all measured values, the non-survivors had a significantly higher 
median of TNF-a levels than the survivors (p=O.OOOl). There was, however, great interpatient and intrapatient variability 
in TNF-a levels; thus, no unequivocal correlation between TNF-a and outcome could be documented. 
Conclusions: Our data indicate that the influence of the infecting organism on TNF-a kinetics is less pronounced than 
that of the underlying disease. 
Key words: TNF-a, sepsis, immunocompetent, immunocompromised, microbiologically documented and non-docu- 
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INTRODUCTION 
Lipopolysaccharide (endotoxin) and lipid A are 
considered to cause shock and organ failure in Gram- 
negative sepsis [1-4]. Endotoxin injection into animals 
and human volunteers results in symptoms similar 
to those in sepsis and septic shock [5-121. Further- 
more, injection of endotoxin into animals and human 
volunteers induces release of tumor necrosis factor-a 
(TNF-a) in serum within minutes [7-11,131. Infusion 
of TNF-a into animals and human volunteers produces 
fever, hypotension, tissue necrosis, tachypnea, tachy- 
cardia, edema, increased pulmonary vascular perme- 
ability and glomerular damage, similar to the effects 
seen in sepsis [6,7,14-171. TNF-a, or elevations of 
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TNF-or, in serum or cerebrospinal fluid have been 
detected in patients with serious bacterial infections, 
sepsis or septic shock [11,18-381. However, injection 
of endotoxin into healthy volunteers sometimes 
resulted in similar or higher TNF-a levels without life- 
threatening symptoms [Ill. Kiener et al. showed that 
both the toxic forms of lipid A and its non-toxic 
derivative, monophosphoryl lipid A, induced equal 
amounts of TNF-a in mice, but only the mice given 
toxic lipid A or endotoxin died [39]. 
TNF-a elevation has also been reported in non- 
infectious disorders (e.g. rheumatoid arthritis, multiple 
sclerosis, systemic lupus erythematosus, allograft re- 
jection) and in infections caused by parasites, Gram- 
positive bacteria and viruses [33,35,36]. The protective 
effects of TNF-a in some infectious mgeases are also 
being discussed [32-341. In some studies the degree of 
TNF-a elevation was closely related to the severity of 
sepsis [11,20,22,24,26,27,29,30,38], while in other 
studies the serum levels of TNF-a varied widely &om 
patient to patient without correlation with severity or 
outcome [21,23,25,28,31,37]. 
Most authors measured TNF-a only at the 
beginning of the infection or during the first 48 h after 
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the infection was diagnosed. Only a few studies 
followed TNF-a levels during the whole course of the 
infection, with diverging results and conclusions 
[22,24,27,31]. We therefore planned to determine 
TNF-a levels during the entire course of microbio- 
logically documented mfections (MDI) and to compare 
these results with those in microbiologically non- 
documented infections (MNDI). 
PATIENTS AND METHODS 
Fifty-eight hospitalized patients, 21 women and 37 
men of mean age 46 years (k15.8 years) in the internal 
medicine ward, with 63 infection episodes during a 7- 
month period, were studied prospectively. Patients 
I l f a n g  the following criteria were included: 
1. Clinical evidence of acute infection. 
2. Temperature >38.2"C. 
3. Tachycardia (>90 beatdmin). 
4. Tachypnea (>20 breathdmin, while the patient was 
spontaneously breathing) or patient on assisted 
ventilation. 
Blood samples were taken (10 mL in a heparin-coated 
endotoxin-fi-ee tube) &om a central line or a peripheral 
vein every day except Saturdays and Sundays between 
7:OO AM and 1O:OO AM. Within 30 min the samples 
were centrifuged, and the serum was stored in aliquots 
in endotoxin-fYee tubes at -8OoC, for measurement of 
TNF-a concentration at a later date. TNF-a concen- 
trations were determined by enzyme immunoassay 
(TNF-a-EASIA, Medgenix Diagnostics, No. 40 175 00, 
Medgenix Group Deutschland GmbH) according to 
the manufacturer's instructions. The detection limit 
was 5 pg/mL TNF-a. Duplicate determinations were 
carried out on each sample. 
The first day of fever was defined as day 1 for 
each episode. All data collected consecutively were 
numbered accordingly. The underlying disease, clinical 
course and outcome, medication, body temperature, 
heart rate, blood pressure, blood count, other laboratory 
data and microbiological findings were documented. 
Data were evaluated &om day 1 to 3 days after 
defervescence, to a maximum of 13 days. For analysis 
and comparison, patients were divided according to 
the following features: outcome; body defense status; 
underlying disease; microbiological findings. 
Statistical analysis 
In t h i s  study median TNF-a levels were used because 
the number of data collected in separate episodes 
Mered. For each group of patients (episodes), defined 
by the above criteria, three median values were 
calculated. Mtod was the median of all the TNF-a 
levels determined in all the episodes in the group. 
M d u m  was the median of the highest TNF-a values 
in the individual episodes included in the group. 
Mepisode was the median of the series composed of the 
median values calculated for the individual episodes 
included in the group. Mrod is thus based on all values 
of all episodes of one group, and in this calculation 
episodes with many TNF-a values have more im- 
portance than episodes with less values. The advantage 
of M-mum and Mepuode is that every episode becomes 
equally important; however, groups might be com- 
posed of dfferent numbers of episodes. The data were 
analyzed exploratively and descriptively using the F-test 
and the Mann-Whitney rank sum test, because there 
was no standard distribution of the data. The false 
probability 'a' was 5%. A probability ofp<O.O5 showed 
a significant Merence between two groups. 
RESULTS 
Thirteen (22.4%) of 58 patients died and 13 of 63 
episodes (20.6%) had a fatal outcome. Nine patients 
died during the study period; four patients died within 
10 days after the last blood sample for TNF-a measure- 
ment had been taken. Mtod of the non-survivors was 
significantly higher than Mtod of the survivors (Table 
1). The same was true for Meplsode (p=0.032). There 
was no significant Merence with respect to M-, 
(p=0.056). 
In 29 episodes (46.0%) the infection was micro- 
biologically confirmed. Blood cultures yielded Gram- 
positive bacteria in 13 episodes and Gram-negative 
bacteria in nine. In five episodes Plasmodium falciparum 
was found in the blood smear, and in two episodes 
Axpergillus fumigatus at post-mortem examinations. 
Figure 1 shows Mtod calculated for each individual day 
(Mtod(hy)) &om day 1 to day 13, for MDI and for 
MNDI. Mtod(hy) was greater than 53.5 p g / d  only on 
days 1 and 5, and only on these two days was the 
difference between MDI and MNDI greater than 
16.5 pg/mL. Neither MDI nor MNDI Mt0d(+) was 
consistently the higher on the various days. There was 
no significant difference between MDI and MNDI 
with respect to Mtod (for the whole investigation; Table 
I), M,-, or Mepuode (p>0.05, in each case). How- 
ever, Mtod of the episodes with Gram-negative bacteria 
was significantly higher than Mrod when Gram-positive 
bacteria were found (Table 1). There was also a just 
significant difference with respect to Meplsode ( ~ ~ 0 . 0 4 9 )  
but not M-.-,- (p=0.217). 
In 29 episodes (46.0%) the patients were immuno- 
compromised: 14 patients, acute myeloid leukemia 
(AML) (16 episodes); five patients, acquired immuno- 
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Table 1 Episodes, number of samples and median of TNF-a levels in p g / d  (Mtod with minimum and maximum and 
pvalue with respect to survivors and non-survivors, microbiological findings and underlying disease 
Number of 
Episodes samples Minimum MaXinlUm MtCd pvalue 
- -  
I 1 I I . 
I I I 1 I I 
I I 1 I I 
I I I I I I 
SuMvors 
Non-survivors 
MDI 
MNDI 
Gram-positive bacteria 
Gram-negative bacteria 
Primary diagnosis sepsis 
Falciparum malaria 
AIDS 
AML 
50 
13 
29 
34 
13 
9 
7 
5 
5 
16 
188 
53 
110 
131 
53 
30 
26 
20 
21 
58 
0.0 
16.0 
0.2 
0.0 
0.2 
0.5 
0.0 
22.9 
41.2 
0.2 
587.3 
554.9 
242.2 
587.3 
242.2 
222.9 
225.0 
153.9 
479.0 
554.9 
} 0.0001 30.3 
55.3 
37.3 } 0.724 
42.2 
} 0.002 23.7 
48.4 
} 0.018 42.8 
78.6 
} 0.0001 
16.8 
~ ~ ~ ~~ 
AIDS=acqwred lmmunodeficiency syndrome, AML=acute myeloid leukerma. 
MDI= mcrobiologdly documented dechon; MNDI= mcrobiologdly non-documented ifecaon. 
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Figure 1 Median of TNF-(w levels in p g / d  (Mtoal(k)) with respect to microbiologically documented and non- 
documented infections from day 1 to day 13. 
deficiency syndrome (AIDS); two patients, Hodgkm’s seven patients, sepsis; five patients, fdciparum malaria; 
disease (three episodes); two patients, myelodysplastic three patients, pneumonia (four episodes); one patient, 
syndrome; two patients, non-Hodgkin lymphoma; tuberculosis (two episodes); three patients, pancrea- 
and one patient, chronic lymphoproliferative leukemia. titis; three patients, gastrointestinal disorders (two 
In 34 episodes (54.0%) the patients were immuno- diverticulitis of the sigmoid, one ulcerative colitis), 
competent. The primary diagnoses were as follows: four patients, cardiac disorders (one endocarditis, two 
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aortocoronary vein bypass, one empyema of the peri- 
cardium); and six patients, other underlying diseases 
(bronchial asthma, chronic obstructive lung disease, 
hemolysis, angiosarcoma, terminal renal failure, hemo- 
lytic uremic syndrome). Mtod of the immunocom- 
petent patients was significantly higher than Mt0d of 
the immunocompromised patients. With regard to 
M d u m  and Mepisode of TNF-a levels, there was no 
significant difference (p>0.05). 
Table 2 lists the documented microorganisms 
according to the immune status of the patients. In 
Table 2 Microbiological findings according to the immune 
status of the patients 
Immuno- Immuno- 
competent compromised 
Microorganism patients patients 
Staphylococcus aureus' 3 3 
Streptococcus mitis' 0 3 
Streptococcus pneumoniae" 1 0 
Streptococcus group B' 1 0 
Streptococcus viridans' 0 1 
Entwocoats faecalis. 0 1 
Escherichia coli" 3 3 
Stenotrophomonas maltophilia' 1 0 
Pseudomonas aemginosa" 1 0 
Bacteroides jagilis' 1 0 
hpergilkusfumigatus* 1 1 
Plasmodium falcipamm' 5 0 
Subtotal 17 12 
Microbiologically non- 
documented infections 17 17 
Total 34 29 
'Blood culture; bpost-mortem examination; 'blood smear. 
17 episodes in both groups the infection was not 
documented microbiologically. Twelve of 29 infections 
in the immunocompromised, as against 17 of 34 in the 
immunocompetent, were microbiologically proven 
(Table 2). Mtotd values of TNF-a levels according to 
immune status and microbiological findings are given 
in Table 3. Mtod of the immunocompromised patients 
with MNDI was significantly higher than Mt0d of 
those with MDI. This difference was not seen in 
the immunocompetent patients. However, Mtod of the 
TNF-a levels in the immunocompetent patients with 
MDI was significantly higher than that in the immuno- 
compromised patients with MDI, whereas in patients 
with MNDI no significant difference was seen. A 
significant merence was found between Gram-positive 
bacteria and Gram-negative bacteria in the case of 
immunocompromised patients, and between immuno- 
compromised and immunocompetent patients with 
respect to Gram-positive bacteria. Because of the small 
number of patients in each group (Gram-negative or 
Gram-positive), the statistical strength was reduced and 
M- and Meplsode of the TNF-a levels were not 
calculated. In the other cases there was no significant 
difference with regard to M-mm and Meplsode, except 
in MDI. For those cases, there was a higher Meplsode 
among the immunocompetent patients (Mep,sode=57.7 
pg/mL TNF-a) than among the immunocompromised 
patients (Mepnode= 17.6 pg/mL TNF-a) (p=0.021). 
There was a significant difference between patients 
with AIDS and those with AML, and a significant 
difference between patients with a primary diagnosis 
of sepsis and patients with falciparum malaria, with 
respect to Mtod (Table 1). 
Table 3 Episodes, number of samples and median of TNF-cx levels in p g / d  (Mtod) with minimum and maximum and 
p-value with respect to immune status and microbiological findings 
Number of 
Episodes samples Minimum Maximum MtOd 
Immunocompetent 34 130 0.0 587.3 45.5a 
MNDI  
MDI 
Gram-positive bacteria 
Gram-negative bacteria 
17 65 0.0 587.3 42.2b 
17 65 2.7 242.2 46.8' 
6 21 3.8 199.5 46.8' 
5 20 20.0 242.2 44.5d 
Immunocompromised 29 111 0.2 554.9 30.3' 
Gram-positive bacteria 8 33 0.2 130.2 15.7h 
MDI 12 45 0.2 222.9 19.9' 
Gram-negative bacteria 3 9 0.5 222.9 94.49 
MNDI 17 66 0.3 554.9 44.7k 
Additional statistical comparisons: 
a versus f: p=0.014; b versus c: p=0.232; b versus k ~ ~ 0 . 9 8 0 ;  c versus i: p=O.OOOl; d versus e: p=0.540; d versus k p=O.OOOl; e versus f: 
p=0.619; g versus h: p=0.034; i versus k: p=0.032. 
MDI=microbiologically documented infection including Aspergillusfumigatus and Plasmodium fakiparum. MNDI=microbiologically non- 
documented infection. 
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DISCUSSION 
Four lines of evidence support the suggestion that 
TNF-a is a pivotal mediator of sepsis and septic shock. 
TNF-a appears in the blood circulation within minutes 
in experimental sepsis and endotoxemia in humans and 
laboratory animals [7-11,131. TNF-a is detected in the 
serum or cerebrospinal fluid of patients with sepsis and 
with septic shock, and correlated with the severity of 
the sepsis or the outcome in some studies [11,18-381. 
Infusion of TNF-a into animals and humans resulted 
in symptoms and pathologic findings similar to those 
seen in sepsis or septic shock [6,7,14-171. A h n i -  
stration of antibodies against TNF-a in animal models 
of septic shock protected the a d s  against metabolic 
derangements or death [35,40]. In our study, 13 of 58 
patients (22.4%) &ed and 13 of 63 episodes (20.6%) had 
a fatal outcome. A similar death rate has been reported 
by Bone et al. in the sepsis syndrome [41,42]. 
Some studies have shown a correlation between 
TNF-a serum levels and severity of infection, sepsis or 
septic shock. Waage et al. examined serum samples 
&om 79 patients with meningococcal meningitis, 
septicemia, or both [20]. TNF-a was detected in 
samples h m  10 of 11 patients who died but in only 
eight of 68 survivors. All patients (five) with TNF-a 
levels over lOOpg/mL. died. In addition, however, 
some patients with lower levels died, whde some 
patients with higher levels (but lower than 100 pg/mL) 
survived. Girardin et al. reported a direct correlation 
between serum TNF-a concentrations and mortality 
rate in childhood infectious purpura [30]. At a TNF-a 
serum concentration over 500 pg/mL, the mortality 
rate was high. On the day of sepsis onset, 0&er et al. 
found si@icantly higher TNF levels in patients who 
died within 24 h than in survivors or in non-survivors 
who died after 24 h [38]. Cannon et al. demonstrated 
a positive correlation between TNF-a level and 
Apache I1 score in patients with septic shock [l l] .  
However, in the same study, similar or higher TNF-a 
levels were found in healthy volunteers after endotoxin 
infusion, without the development of life-threatening 
symptoms. Calandra et al. showed that TNF-a levels 
were associated with the outcome of patients in septic 
shock 1221. However, the combination of the severity 
of the underlying disease, the age of the patient, the 
documentation of infection, the urine output and the 
arterial pH contributed more signlficantly to prediction 
of outcome than serum levels of TNF-a. Debets et al. 
found that detection of TNF-a and the patient’s 
outcome were correlated [29]. TNF-a was detected in 
11 of 43 patients with sepsis. Eight of these 11 patients 
died, while only 11 of 32 patients without a detectable 
TNF-a level died. There was, however, a great 
range in TNF-a levels (10-100 pg/mL). In addition, 
Hammerle et al. and Marks et al. reported a correlation 
of TNF-a level and severity of sepsis or septic shock, 
and detection of TNF-a discriminated between sepsis 
or septic shock and shock h m  other cause [24,27]. 
According to Dofferhoff et al., TNF-a levels can 
discriminate between sepsis and non-sepsis, but they 
found no correlation between TNF-a and Apache I1 
score, whereas interleulun-6 (IL-6) was correlated with 
the Apache I1 score [23]. Fisher et al. reported that IL- 
6, but not TNF-a, predicted a fatal outcome in patients 
with sepsis or septic shock, but neither TNF-cx nor IL- 
6 correlated with Apache I1 score [31]. However, 
TNF-a levels were higher in patients with septic shock 
than in those without septic shock. Casey et al. found 
a correlation between IL-6 and outcome in patients 
with sepsis syndrome but not between TNF-a con- 
centrations and outcome [21]. The combination of 
interleukin-1 p, IL-6, TNF-a and endotoxin level 
(lipopolysaccharide-cytokine scoring) correlated more 
significantly with the patient’s outcome. According to 
a study of Pinsky et al., there was no correlation 
between maximum TNF-a level and outcome, but a 
discrimination between septic shock and non-septic 
shock was possible [25]. de Groote et al. &d not find a 
correlation between TNF-a level and the severity of 
sepsis [37]. Indeed, TNF-a was detected in only 14 
samples from six patients among 188 samples from 38 
patients with sepsis. Sdar ly ,  Harris et al. did not find 
a correlation between TNF-a and severity of disease in 
children with sepsis or enterocolitis, or both [28]. 
In most of the studies [11,20,21,23,25,28-301, 
TNF-a was measured only at the beginning of the 
episodes or within the first 48 h after infection was 
diagnosed. In contrast, Calandra et al. measured TNF- 
a levels on day 0, day 1 and day 10 and described a 
decrease of TNF-a levels in survivors, in contrast to 
non-survivors [22]. Marks et al. found that TNF-cx 
levels were highest in the initial samples and decreased 
during the subsequent 24 h [24]. In accordance with 
other studies, including some of those which described 
a correlation of TNF-a level and severity of sepsis 
[11,20-27,371, in our study TNF-a concentrations 
varied widely h m  patient to patient, from non- 
detectable up to 587.3 pg/mL. We found not only high 
initial TNF-a levels but also an increase in the course 
of sepsis. There were also episodes during which low 
initial levels gave place to high levels, and vice versa. 
Thus the TNF-a levels varied widely &om patient to 
patient, but also widely within each individual patient 
episode. The interpatient heterogeneity of the TNF-a 
response might be explained by the findings of Stiiber 
et al. [43]. They found in patients with severe sepsis 
higher circulating TNF-a concentrations as well as 
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higher multiple organ failure scores in patients homo- 
zygous for the allele TNFB2 compared with hetero- 
zygous (TNFBl/TNFB2) patients. In contrast to most 
other investigators [20,21,24,29,37], who detected 
TNF-a in only 16-54% of cases, we detected TNF-a 
in 87% of the samples. In only four patients was TNF- 
a not detected at any time during the whole episode. 
Calandra et al. detected TNF-a in 79% of the patients, 
Dofferhoff et al. in 94% and Girardin et al. in 91% 
[22,23,30]. In our study the non-survivors had a 
significantly higher Mtod of TNF-a levels than the 
survivors (p=O.OOOl), but there was not an unequivocal 
correlation between TNF-a level and outcome or 
severity of the infection, as described in other studies 
11 1,20,22,24,26,27,29,30,38]. There was also a positive 
correlation with regard to Meplrode (p=0.032), but 
not with regard to Mmum (p=0.056). Pinsky et al. 
reported a positive correlation of TNF-a levels with 
respect to all measured values at 0, 1, 2, 4, 12, 24 and 
48 h but not to the peak levels [25]. In a longitudinal 
study of Munoz et al., initial or maximum levels of 
TNF-a among surviving and non-surviving septic 
patients were not statistically Merent, whereas IL-6 
plasma levels (initial as well as maximum) correlated 
with outcome [44]. Baud et al. described no correlation 
between serum TNF-a levels in patients with septic 
shock on admission and outcome. However, persistent 
high TNF-a serum levels during the initial 3 days of 
hospitalization were always associated with fatal out- 
come, whereas there was a progressive decline of its 
concentration in all but one of the patients who 
survived [45]. Hammerle et al. found an increase of 
TNF-a levels in patients with sepsis 3 days before 
multiple organ failure occurred [27]. In some cases we 
also detected high TNF-a levels before patients died. 
However, the interpatient and intrapatient variabhty in 
our study reduced not only the statistical strength of 
most comparisons but also the prognostic value of 
Several factors could potentially confound the 
comparison of the TNF-a levels: the lack of stan- 
dardization of the assays used in the different studies, 
the short half-life of TNF-a, the time at which the 
samples were collected relative to the onset of sepsis, 
the time delay before the aliquots were processed, the 
temperature at which the samples were stored, the 
effects of circulating soluble TNF-a receptors, or the 
addition of, for example, heparin or EDTA [21,46-501. 
In accordance with other studies [41,42,51] with 
similar inclusion criteria, in our study 46% of the 
episodes were microbiologically documented. With 
respect to Mmd, there was no sigmficant difference of 
TNF-a levels between microbiologically documented 
versus non-documented episodes (p=0.724), but there 
TNF-a. 
was between Gram-positive and Gram-negative bacterial 
causes (p=0.002). This difference was in agreement 
with other studies [21,31] which did not show similarly 
high values in the patients with microbiologically non- 
documented infection. Other authors [24-26,281 did 
not report different TNF-a levels in microbiologically 
proven and unproven sepsis. 
As reported by other authors, we found high TNF- 
a levels in falciparum malaria [52-561, and also [33,57, 
581 high TNF-a levels in patients with AIDS. A direct 
correlation between TNF-a and severity of disease in 
patients with HIV infection has been reported [57]. In 
our study, lower levels of TNF-a, with regard to Mod, 
were found in patients with AML; some patients, 
however, had very high levels. Only a few reports are 
available on the relevance of TNF-a in patients with 
leukemia, especially AML [59-631. Foa et al. reported 
that TNF-a plays an important role in the pathogenesis 
of the pancytopenia commonly associated with hairy 
cell leukemia [62]. 
The results of the present study cannot be com- 
pared directly with the published data, because of 
vast difTerences in the inclusion criteria and the time 
period during which TNF-a levels were monitored. 
The influence of the infecting organism on TNF-a 
kinetics seem to be less pronounced than that of 
the underlying disease. The role of TNF-a and its 
prognostic value in severe sepsis or septic shock remains 
to be defined. 
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